Predictive value of <scp>post‐treatment C‐reactive protein‐to‐albumin</scp> ratio in locally advanced <scp>non–small</scp> cell lung cancer patients receiving durvalumab after chemoradiotherapy

Abstract

This study suggests that post-treatment CAR has predictive value for LA-NSCLC patients treated with CCRT plus durvalumab consolidation therapy.